Double bone marrow transplantation for severe aplastic anemia after orthotopic liver transplantation: Implications for clinical management and immune tolerance

Transplant International

Volumn 15, Issue 1, 2002, Pages 39-44

  Stachel, Daniel ^a   Schmid, Irene ^b   Lang, Thomas ^b   Haas, Rainer J ^b   Otté, Jean Bernard ^c  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

Author keywords

Clinical management tolerance; Double bone marrow transplantation; Orthotopic liver transplantation Childhood

Indexed keywords

CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; GANCICLOVIR; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; LYMPHOCYTE ANTIBODY; METHOTREXATE; TACROLIMUS; THYMOCYTE ANTIBODY;

APLASTIC ANEMIA; ARTICLE; BONE MARROW TRANSPLANTATION; CASE REPORT; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG MEGADOSE; GRAFT REJECTION; HUMAN; HUMAN TISSUE; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; LIVER FAILURE; LIVER TRANSPLANTATION; LOW DRUG DOSE; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; RECURRENT DISEASE; TREATMENT OUTCOME;

ADRENAL CORTEX HORMONES; ANEMIA, APLASTIC; BONE MARROW TRANSPLANTATION; CASE REPORT; CHILD, PRESCHOOL; CYCLOSPORINE; GRAFT REJECTION; HUMAN; IMMUNE TOLERANCE; IMMUNOSUPPRESSIVE AGENTS; LIVER FAILURE; LIVER TRANSPLANTATION; MALE; TRANSPLANTATION CONDITIONING;

EID: 0036937044     PISSN: 09340874     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1432-2277.2002.tb00096.x     Document Type: Article

References (24)

1. Abu-Elmagd K, Fung J, Todo S, Rao A, Reyes J, Demetris AJ, Mazariegos G, Fontes P, McMichael J, Furukawa H, Dodson F, Jain A, Pinna A, Marsh W, Marino I, Gayowski T, Doyle H, Madariaga J, Casavilla A, Corry R, Rakela J, Iwatsuki S, Starzl TE (1996) The current status of hepatic transplantation at the University of Pittsburgh. In: Terasaki PI, Cecka JM (eds) Clinical transplants 1995. UCLA Tissue Typing Laboratory, Los Angeles, pp 145-170
2. Cattral MS, Langnas AN, Markin RS, Antonson DL, Heffron TG, Fox IJ, Sorrell MF, Shaw BW Jr (1994) Aplastic anemia after liver transplantation for fulminant liver failure. Hepatology 20:813-818
3. Comenzo RL, Malachowski ME, Rohrer RJ, Freeman RB, Rabson A, Berkman EM (1992) Anomalous ABO phenotype in a child after an ABO-incompatible liver transplantation. N Engl J Med 326:867-870
4. Dey B, Sykes M, Spitzer TR (1998) Outcomes of recipients of both bone marrow and solid organ transplants. A review. Medicine (Baltimore) 77: 355-369
5. Fay JW, Wingard JR, Antin JH, Collins RH, Pineiro LA, Blazar BR, Saral R, Bierer BE, Przepiorka D, Fitzsimmons WE, Maher RM, Weisdorf DJ (1996) FK506 (tacrolimus) monotherapy for prevention of graft-versus-host disease after histocompatible sibling allogenic bone marrow transplantation. Blood 87:3514-3519
6. Garcia Morales R, Carreno M, Mathew J, Cirocco R, Zucker K, Ciancio G, Burke G, Roth D, Temple D, Fuller L, Esquenazi V, Eskind L, Kenyon NS, Ricordi C, Tzakis A, Miller J (1998) Continuing observations on the regulatory effects of donor-specific bone marrow cell infusions and chimerism in kidney transplant recipients. Transplantation 65:956-965
7. Haas RJ, Schmid I, Schon C, Soballa Stehr E, Stachel D (1999) Non-Hodgkin lymphoma after heart-lung transplantation: response to chemotherapy. Med Pediatr Oncol 32:229-230
8. Kanamaru A, Takemoto Y, Kakishita E, Dohy H, Kodera Y, Moriyama Y, Shibata A, Kasai M, Katoh S, Saitoh H (1995) FK506 treatment of graft-versus-host disease developing or exacerbating during prophylaxis and therapy with cyclosporin and/or other immunosuppressants. Japanese FK506 BMT Study Group. Bone Marrow Transplant 15:885-889
9. Kawahara K, Storb R, Sanders J, Petersen FB (1991) Successful allogeneic bone marrow transplantation in a 6.5-year-old male for severe aplastic anemia complicating orthotopic liver transplantation for fulminant non-A-non-B hepatitis. Blood 78:1140-1143
10. Langnas AN, Markin RS, Cattral MS, Naides SJ (1995) Parvovirus B19 as a possible causative agent of fulminant liver failure and associated aplastic anemia. Hepatology 22:1661-1665
11. Lee TH, Donegan E, Slichter S, Busch MP (1995) Transient increase in circulating donor leukocytes after allogeneic transfusions in immunocompetent recipients compatible with donor cell proliferation. Blood 85:1207-1214
12. Mazariegos GV, Reyes J, Marino IR, Demetris AJ, Flynn B, Irish W, McMichael J, Fung JJ, Starzl TE (1997) Weaning of immunosuppression in liver transplant recipients. Transplantation 63:243-249
13. Myburgh JA, Smit JA, Stark JH, Browde S (1984) Total lymphoid irradiation in kidney and liver transplantation in the baboon: prolonged graft survival and alterations in T cell subsets with low cumulative dose regimens. J Immunol 132:1019-1025
14. Nakamura T, Good RA, Yasumizu R, Inoue S, Oo MM, Hamashima Y, Ikehara S (1986) Successful liver allografts in mice by combination with allogeneic bone marrow transplantation. Proc Natl Acad Sci USA 83:4529-4532
15. Nash RA, Pineiro LA, Storb R, Deeg HJ, Fitzsimmons WE, Furlong T, Hansen JA, Gooley T, Maher RM, Martin P, McSweeney PA, Sullivan KM, Anasetti C, Fay JW (1996) FK506 in combination with methotrexate for the prevention of graft-versus-host disease after marrow transplantation from matched unrelated donors. Blood 88: 3634-3641
16. Pardi DS, Romero Y, Mertz LE, Douglas DD (1998) Hepatitis-associated aplastic anemia and acute parvovirus B19 infection: a report of two cases and a review of the literature. Am J Gastroenterol 93:468-470
17. Ramos HC, Reyes J, Abu Elmagd K, Zeevi A, Reinsmoen N, Tzakis A, Demetris AJ, Fung JJ, Flynn B, McMichael J (1995) Weaning of immunosuppression in long-term liver transplant recipients. Transplantation 59:212-217
18. Ratanatharathorn V, Nash RA, Przepiorka D, Devine SM, Klein JL, Weisdorf D, Fay JW, Nademanee A, Antin JH, Christiansen NP, van der Jagt R, Herzig RH, Litzow MR, Wolff SN, Longo WL, Petersen FB, Karanes C, Avalos B, Storb R, Buell DN, Maher RM, Fitzsimmons WE, Wingard JR (1998) Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation. Blood 92:2303-2314
19. Ricordi C, Karatzas T, Nery J, Webb M, Selvaggi G, Fernandez L, Khan FA, Ruiz P, Schiff E, Olson L, Fernandez H, Bean J, Esquenazi V, Miller J, Tzakis AG (1997) High-dose donor bone marrow infusions to enhance allograft survival: the effect of timing. Transplantation 63:7-11
20. Selvaggi G, Ricordi C, Bottino R, Tzakis AG (1996) Liver transplantation without immunosuppression: future perspectives. Ital J Gastroenterol 28:246-249
21. Smit JA, Hill RR, Myburgh JA, Browde S (1980) Transplantation tolerance in primates after total lymphoid irradiation and allogeneic bone marrow injection. III. Lymphocyte responsiveness and suppressor cell activity. Transplantation 30:107-110
22. Trede NS, Warwick AB, Rosoff PM, Rohrer R, Bierer BE, Guinan E (1997) Tacrolimus (FK506) in allogeneic bone marrow transplantation for severe aplastic anemia following orthotopic liver transplantation. Bone Marrow Transplant 20:257-260
23. Tzakis AG, Arditi M, Whitington PF, Yanaga K, Esquivel C, Andrews WA, Makowka L, Malatak J, Freese DK, Stock PG, Ascher NL, Johnson FL, Broelsch CE, Starzl TE (1988) A plastic anemia complicating orthotopic liver transplantation for non-A, non-B hepatitis. N Engl J Med 319:393-396
24. Whitington PF, Rubin CM, Alonso EM, McKeithan TW, Anastasi J, Hart J, Thistlethwaite JR (1996) Complete lymphoid chimerism and chronic graft-versus-host disease in an infant recipient of a hepatic allograft from an HLA-homozygous parental living donor. Transplantation 62:1516-1519